Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Stocks

Dr. Lal PathLabs Grows at 30%, Increases Stake in Subsidiaries : Result Analysis

Dr.-Lal-Path-Labs-Q12017-Results-Analysis.png

Dr. Lal PathLabs Limited  – the Delhi based international service provider of diagnostic and related healthcare tests reported its performance for JunDr. Lal Logo 2016.
Remember this was the company whose IPO was over subscribed by 33.41 time and the stock has been hitting highs since listing. The stock hit its 52 week low at Rs. 696.5/- in early January and currently trails at over Rs. 950/-.

Dr. Lal Path Labs Share Price 29 JulyResult Analysis: Dr. Lal Path Labs

  • Total Income from Operations increased 17.71% to Rs. 222.8 crore.
  • Profit After tax increased 29.66% to Rs. 40.17 crore.
  • EPS increased 28.5% to Rs. 4.78 per share.

Other notable points were:

  • Other Income increased from Rs. 4.11 crore to Rs. 6.01 crore.
  • Tax Expense noticed a bump of Rs. 10 crore from Rs. 30.98 crore.
  • During the quarter, the company acquired an additional 10% stake in its two subsidiaries i.e. Paliwal Diagnostics and Paliwal Medicave thereby now holding 80% stake in both the companies.

Dr. Lal Path Labs Q12017 Results Analysis
Disclosure: Analyst or Family do not hold the stock
Capital Mind divider

Disclaimer

Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.